<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alirocumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alirocumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alirocumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="103203" href="/d/html/103203.html" rel="external">see "Alirocumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F29046652"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Praluent</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871981"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Praluent</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28895637"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, PCSK9 Inhibitor;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F29046483"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use may be considered in patients who do not meet cholesterol treatment goals with dietary modification and other lipid-lowering therapies (ie, maximally tolerated statin plus ezetimibe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586774'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be04224c-8e9d-4248-8315-86a413718095">Homozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia: SUBQ:</b> 150 mg once every 2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="586a035f-1fb9-4034-819b-9f11a8885780">Hyperlipidemia, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia, primary: SUBQ:</b> Initial: 75 mg once every 2 weeks<b> or </b>300 mg once every 4 weeks; for both regimens, if an adequate low-density lipoprotein cholesterol (LDL-C) response is not achieved, may increase or modify dosing regimen to a maximum of 150 mg every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Heterozygous familial hypercholesterolemia undergoing LDL apheresis:</i> SUBQ:</b> 150 mg once every 2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e53d3ae-950b-4973-b4a0-b555bb66adab">Secondary prevention of cardiovascular events</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary prevention of cardiovascular events:</b>
<b>SUBQ:</b> Initial: 75 mg once every 2 weeks <b>or</b> 300 mg once every 4 weeks; for both regimens, if an adequate LDL-C response is not achieved, may increase or modify dosing regimen to a maximum dose of 150 mg every 2 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching regimens:</b> When switching from the monthly regimen to an every-2-week regimen, start the new dose on the next scheduled dosing date; reassess LDL-C 4 to 8 weeks after dosing change.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> If a dose is missed ≤7 days from the usual day of administration, administer the dose as soon as possible and then resume the original schedule; otherwise, if beyond 7 days, skip the missed dose and resume the normal dosing schedule, or if dosage is monthly, start a new schedule based on this date.</p></div>
<div class="block dora drugH1Div" id="F50990386"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment is unlikely to be required as monoclonal antibodies are not known to be renally eliminated.</p></div>
<div class="block doha drugH1Div" id="F50987473"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F29046484"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F29112583"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Injection site reaction (4% to 17%, including erythema at injection site, injection site pruritus, pain at injection site, swelling at injection site, tenderness at injection site)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (&gt;3 x ULN: 2%), liver enzyme disorder (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (9%, including nummular eczema and hypersensitivity angiitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (6%; neutralizing: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (3%), myalgia (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms</p></div>
<div class="block coi drugH1Div" id="F28872100"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Serious hypersensitivity to alirocumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F29046465"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including some severe reactions requiring hospitalization (eg, hypersensitivity vasculitis, angioedema), have been reported. Discontinue treatment and initiate supportive treatment in patients who develop serious allergic reaction. Other hypersensitivity reactions, including pruritus, rash, and urticaria, have been reported.</p></div>
<div class="block foc drugH1Div" id="F29046653"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Praluent: 75 mg/mL (1 mL); 150 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Praluent: 75 mg/mL (1 mL [DSC]); 150 mg/mL (1 mL [DSC]) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block geq drugH1Div" id="F29046462"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F29835912"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Praluent Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg/mL (per mL): $303.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $303.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871982"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Praluent: 75 mg/mL (1 mL); 150 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Praluent: 75 mg/mL ([DSC]); 150 mg/mL ([DSC]) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block accres drugH1Div" id="F44404614"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Only available via specialty pharmacies. Call 844-772-5836 or visit https://www.praluenthcp.com/support for additional information.</p></div>
<div class="block adm drugH1Div" id="F29046488"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Allow solution to come to room temperature for 30 to 40 minutes prior to administration; do not warm in any other way. Do not shake. Administer by SUBQ injection into the thigh, abdomen (avoiding the 2-inch area around the navel), or upper arm; rotate injection site with each injection; may take up to 20 seconds for full dose to be injected. For the 300 mg dose, administer two 150 mg injections consecutively at 2 different injection sites. Do not inject into skin that is tender, bruised, hard, red hot or damaged, or has visible veins, scars, or stretch marks. Do not coadminister with other injectable drugs at the same injection site. Do not reuse prefilled pens/syringes; single use only. Do not administer if window on pen/syringe is solid yellow (indicates pen/syringe has been used). Do not use prefilled syringe if blue cap is missing or loose, if it has been dropped, or if damaged; avoid touching yellow safety cover. For patients undergoing LDL apheresis, may be administered without regard to the timing of apheresis.</p></div>
<div class="block use drugH1Div" id="F28872099"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia</b>
<b>: </b>Adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies in adults with homozygous familial hypercholesterolemia to reduce LDL-C.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia, primary:</b> Adjunct to diet, alone or in combination with other LDL-C lowering therapies in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary prevention of cardiovascular events: </b>To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease (Schwartz 2018).</p></div>
<div class="block cyt drugH1Div" id="F29043789"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F29043786"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F29046463"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Alirocumab is a humanized monoclonal antibody (IgG1). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of alirocumab during pregnancy are limited (Vuignier 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to alirocumab is ongoing. Health care providers are encouraged to report exposures of alirocumab during pregnancy (1-844-734-6643).</p></div>
<div class="block brc drugH1Div" id="F29046464"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if alirocumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Alirocumab is a humanized monoclonal antibody (IgG1). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021). Serum concentrations to a breastfeeding infant are not expected to be substantial. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of exposure to the breastfed infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F29046490"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Lipid profile (fasting or nonfasting) before initiating treatment. Fasting lipid profile should be rechecked 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter (AHA/ACC [Grundy 2018]). For patients receiving 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose (LDL-C varies considerably between doses with this regimen). Monitor for hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F29046469"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Alirocumab is a human monoclonal antibody (IgG1isotype) that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on hepatocyte surfaces to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL; therefore, the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.</p></div>
<div class="block phk drugH1Div" id="F29046474"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Peak effect: Proprotein convertase subtilisin kexin type 9 (PCSK9) suppression: 4 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: V<sub>d</sub>: ~0.04 to 0.05 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Expected to undergo proteolysis and be degraded to small peptides and amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: ~85%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SUBQ: Steady-state: 17 to 20 days; reduced to 12 days when administered with a statin.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: SUBQ: 3 to 7 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45649917"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Praluent | Praluente</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Praluent</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol [published online November 10, 2018]. <i>Circulation</i>. 2018. doi: 10.1161/CIR.0000000000000625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911072">
<a name="25911072"></a>Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/25911072/pubmed" id="25911072" target="_blank">25911072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26027630">
<a name="26027630"></a>Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>Am Heart J</i>. 2015;169(6):906-915.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/26027630/pubmed" id="26027630" target="_blank">26027630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Regeneron.1">
<a name="Regeneron.1"></a>Praluent (alirocumab) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25773378">
<a name="25773378"></a>Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. <i>N Engl J Med</i>. 2015;372(16):1489-1499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/25773378/pubmed" id="25773378" target="_blank">25773378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.1">
<a name="Rosenson.1"></a>Rosenson RS. Low density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25037695">
<a name="25037695"></a>Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. <i>Int J Cardiol</i>. 2014;176(1):55-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/25037695/pubmed" id="25037695" target="_blank">25037695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25440796">
<a name="25440796"></a>Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. <i>Am Heart J.</i> 2014;168(5):682-689. doi: 10.1016/j.ahj.2014.07.028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/25440796/pubmed" id="25440796" target="_blank">25440796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30403574">
<a name="30403574"></a>Schwartz GG, Steg PG, Szarek M, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. <i>N Engl J Med.</i> 2018;379(22):2097-2107. doi: 10.1056/NEJMoa1801174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/30403574/pubmed" id="30403574" target="_blank">30403574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34105316">
<a name="34105316"></a>Vuignier Y, Beaud F, Kosinski C, et al. Exposure to alirocumab during the first trimester of pregnancy: a case report. <i>Birth Defects Res</i>. 2021;113(15):1156-1160. doi:10.1002/bdr2.1930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alirocumab-drug-information/abstract-text/34105316/pubmed" id="34105316" target="_blank">34105316</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 103073 Version 162.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
